Statins, aspirin and risk of thromboembolic events in ovarian cancer patients
Authors:
- 11 March 2014
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 133 (2) , 304-308
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survivalEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2013
- Effect of ovarian tumor characteristics on venous thromboembolic riskJournal of Gynecologic Oncology, 2013
- Statins, inflammation and deep vein thrombosis: a systematic reviewJournal of Thrombosis and Thrombolysis, 2012
- Thirty-day mortality rate in women with cancer and venous thromboembolism. Findings from the RIETE RegistryThrombosis Research, 2011
- HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosisJournal of Thrombosis and Haemostasis, 2009
- Stratification of Venous Thromboembolism Risk in Ovarian Cancer Patients During ChemotherapyInternational Journal of Gynecological Cancer, 2009
- Incidence of Venous Thromboembolism in Patients With Ovarian Cancer Undergoing Platinum/Paclitaxel–Containing First-Line Chemotherapy: An Exploratory Analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study GroupJournal of Clinical Oncology, 2008
- HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal womenJournal of Thrombosis and Haemostasis, 2004
- Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosisBlood, 2002
- Use of Statins and the Subsequent Development of Deep Vein ThrombosisArchives of internal medicine (1960), 2001